Vanda Pharmaceuticals (VNDA) Revenue (2010 - 2026)

Vanda Pharmaceuticals has disclosed Revenue across 17 years of filings, most recently posting $51.7 million for Q1 2026.

• Revenue for Q1 2026 came in at $51.7 million, up 3.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $217.8 million (up 8.16% YoY), and the FY2025 annual result was $216.1 million, up 8.72% from the prior year.
• Revenue came in at $51.7 million for Q1 2026 at Vanda Pharmaceuticals, down from $57.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $65.3 million in Q3 2022 to a low of $38.8 million in Q3 2023.
• The 5-year median for Revenue is $52.6 million (2025), against an average of $53.7 million.
• Across the five-year window, Revenue slumped 40.58% in 2023 and advanced 22.76% in 2024, its largest moves.
• Vanda Pharmaceuticals' Revenue stood at $64.5 million in 2022, then slipped by 29.79% to $45.3 million in 2023, then grew by 17.48% to $53.2 million in 2024, then gained by 7.58% to $57.2 million in 2025, then retreated by 9.61% to $51.7 million in 2026.
• The last three Revenue figures came in at $51.7 million (Q1 2026), $57.2 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.